The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular carcinoma: an update including recent literature findings

作     者：Walid SAyoub Francis Dailey Paul Martin Patricia DJones 

作者机构：Department of Gastroenterology and HepatologyCedars Sinai Medical CenterLos AngelesCA90048USA David Geffen School of MedicineUniversity of California Los AngelesLos AngelesCA90095USA Division of HepatologyDepartment of MedicineUniversity of Miami Miller School of MedicineUniversity of MiamiMiamiFL33136USA Sylvester Comprehensive Cancer CenterUniversity of MiamiMiamiFL33136USA. 

出 版 物：《Hepatoma Research》 (肝癌研究（英文版）)

年 卷 期：2017年第3卷第12期

页      面：302-308页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Liver cancer hepatocellular carcinoma hepatitis B nucleos(t)ides entecavir tenofovir lamivudine 

摘      要：Worldwide, hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality. In men, it is the fifth most common cancer and seventh most common in women;HCC is the second highest cause of cancer-related death worldwide. It is less prevalent in the USA and Northern Europe and more prevalent in Eastern and South-Eastern Asia. Over 700,000 cases are diagnosed each year - half of which occur in China - and result in roughly the same number of deaths per year. HCC significantly impairs quality of life and is associated with great costs to society. It is estimated that half of the deaths from HCC are associated with hepatitis B virus (HBV). Fortunately, HBV vaccination and antiviral therapy have shown excellent efficacy in decreasing the incidence of HCC. We will discuss the relationship of HBV to HCC, address available treatments for HBV and the impact of treatment on the development of HCC.